Page 5 - Polyphor Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Polyphor to extend period for its strategic evaluation by up to four weeks Polyphor AG / Key word(s): Statement 30-Jul-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, July 30, 2021 Polyphor to extend period for its strategic evaluation by up to four weeks Polyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation of strategic options. This review has become necessary following the negative results of the FORTRES...

EQS-Adhoc: Polyphor AG: Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an 16.07.2021 / 07:30 CET/CEST Veröffentlichung einer Ad-hoc-Mitteilung gemäss Art. 53 KR Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Allschwil, Schweiz, 16. Juli 2021 Polyphor gibt Update zur Zukunft der FORTRESS-Studie mit Balixafortide und kündigt erste Restrukturierungsschritte an - Das Unternehme...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With ... Polyphor AGJune 28, 2021 GMT Co-primary endpoint of the study objective response rate (ORR) was not met The board of directors is undergoing a strategic assessment regarding the future of the company ALLSCHWIL, Switzerland, June 28, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN), a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecu...

Polyphor AG / Key word(s): Study results28-Jun-2021 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Allschwil, Switzerland, June 28, 2021Polyphor provides update on the Phase III FORTRESS study of balixafortide in patients...

Neutrophil elastase inhibitator Market A new report titled, “Global neutrophil elastase inhibitator Market” has been added into its vast repository by